Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Treasury Shares (2016 - 2025)

Seres Therapeutics' Treasury Shares history spans 11 years, with the latest figure at $100824.0 for Q3 2025.

  • For Q3 2025, Treasury Shares fell 96.34% year-over-year to $100824.0; the TTM value through Sep 2025 reached $100824.0, down 96.34%, while the annual FY2024 figure was $81459.0, 97.59% down from the prior year.
  • Treasury Shares for Q3 2025 was $100824.0 at Seres Therapeutics, up from $51199.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $4.2 million in Q1 2023 and bottomed at $51199.0 in Q2 2025.
  • The 5-year median for Treasury Shares is $1.6 million (2022), against an average of $1.8 million.
  • The largest annual shift saw Treasury Shares skyrocketed 11203.92% in 2021 before it crashed 98.66% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $734755.0 in 2021, then surged by 110.89% to $1.5 million in 2022, then surged by 117.99% to $3.4 million in 2023, then plummeted by 97.59% to $81459.0 in 2024, then rose by 23.77% to $100824.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Treasury Shares are $100824.0 (Q3 2025), $51199.0 (Q2 2025), and $76477.0 (Q1 2025).